Lamberto Andreotti

Type: Person
Name: Lamberto Andreotti
First reported 1 hour ago - Updated 1 hour ago - 1 reports

Bristol-Myers and Ono collaborate to develop immunotherapies for cancer

Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd. have signed a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens for treatment of cancer in Japan, South ... [Published Individual.com - 1 hour ago]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Bristol-Myers Squibb Reports Second Quarter 2014 Financial Results

Bristol-Myers Squibb Company has reported financial results for the second quarter of 2014, which was highlighted by strong global sales for the company's key brands; the achievement of important regulatory milestones for key brands in Japan, Europe and ... [Published PharmaAsia - Jul 28 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Bristol-Myers inks Asia immunotherapy deal with Japan's Ono

In a deal that will build on their existing mutual relationship, Bristol-Myers Squibb ($BMY) and Ono Pharmaceutical have formed a pact to bring immunotherapies to market in Japan, South Korea and Taiwan.Under the agreement, Bristol-Myers and Japan's Ono ... [Published FierceBiotech - Jul 25 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Bristol-Myers Squibb Company Taps Bay Area's Redwood City For Expansion, Pharma Giant To Increase Workforce

July 25, 2014By Renee Morad , BioSpace.com Breaking News StaffBristol-Myers Squibb Co. ( BMY ) has taken the first steps toward expanding its office space and building a cancer research hub for drugs that stimulate the immune system to fight cancer.BioMed ... [Published BioSpace - Jul 25 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Bristol-Myers Squibb reports strong operating results for Q2 2014

:56 in Pharmaceutical Company Financials Bristol-Myers Squibb has highlighted the strong progress it has made in the second quarter of 2014, during which it generated a revenue total of $3.89 billion (2.29 billion pounds). This represented a four percent ... [Published Zenopa - Jul 25 2014]
First reported Jul 24 2014 - Updated Jul 25 2014 - 3 reports

Bristol-Myers Squibb Company's (BMY) CEO Lamberto Andreotti Q2 2014 Results - Earnings Call Transcri …

Bristol-Myers Squibb Company (BMY) Q2 2014 Earnings Conference Call July 24, 2014 10:30 PM ETExecutivesJohn Elicker - SVP, Public Affairs and IRLamberto Andreotti - CEOCharlie Bancroft - EVP and CFOGiovanni Caforio - EVP and CCOFrancis Cuss - CSOAnal ... [Published Yahoo! Finance - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Bristol Myers-Squibb 2nd-qtr sales dip 4% but still better than expected

US drug major Bristol-Myers Squibb (NYSE: BMY) has reported second-quarter 2014 results, which show a 4% decline on total revenues to $3.9 billion over the same period last year.Despite being down on second quarter figures for 2013, Reuters reported that ... [Published Pharma Letter - Jul 24 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 1 reports

Bristol-Myers receives approval from MHLW for hepatitis C drug

Bristol-Myers Squibb Company has received approval from the Japanese Ministry of Health, Labor and Welfare, or MHLW, for Daklinza, a potent, pan-genotypic NS5A replication complex inhibitor, and Sunvepra, a NS3/4A protease inhibitor, providing a treatment ... [Published Individual.com - Jul 14 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

CEO’s Letter: The stubborn facts about the 100 Best Corporate Citizens List

CEO’s Letter: The stubborn facts about the 100 Best Corporate Citizens ListElliot H. Clark, CEO“Facts are stubborn things; and whatever may be our wishes, our inclinations, or the dictates of our passion, they cannot alter the state of facts and evid ... [Published CRO - Jul 09 2014]
First reported Jul 07 2014 - Updated Jul 08 2014 - 2 reports

Bristol-Myers Squibb Treatment for Hepatitis C Approved

Tweet[embedded content]Japan approved the all-oral Sunvepra and Daklinzadual regimen from Bristol-Myers Squibb to treat those with hepatitis C, said the company on Monday.The combo-treatment, which is ribavirin- and interferon-free is the latest options ... [Published Zolmax News - Jul 07 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

Bristol-Myers' hep C combo wins Japanese OK, leading the pack

Bristol-Myers Squibb ($BMY) has become the first drugmaker to win regulatory approval for a combination hepatitis C treatment that doesn't require painful injections, picking up a Japanese nod for its all-oral cocktail.The country's Ministry of Health, ... [Published FierceBiotech - Jul 07 2014]
First reported Jun 27 2014 - Updated Jun 28 2014 - 1 reports

Eliquis scores DVT/PE recommendation in Europe

Right now, Eliquis, the new-age clot-fighter from Pfizer ($PFE) and Bristol-Myers Squibb ($BMY), is in third place in a three-horse race. But as it tries to catch up to rivals Pradaxa and Xarelto--not to mention the $3-billion-per-year sales forecasts ... [Published FiercePharma - Jun 27 2014]

More Content

All (29) | News (29) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Bristol-Myers and Ono collaborate to develop im... [Published Individual.com - 1 hour ago]
Bristol-Myers Squibb Reports Second Quarter 201... [Published PharmaAsia - Jul 28 2014]
Bristol-Myers inks Asia immunotherapy deal with... [Published FierceBiotech - Jul 25 2014]
Bristol-Myers Squibb Company Taps Bay Area's Re... [Published BioSpace - Jul 25 2014]
Bristol-Myers Squibb reports strong operating r... [Published Zenopa - Jul 25 2014]
BMS, Ono Pharma sign pact to develop and commer... [Published PharmaBiz - Jul 25 2014]
Bristol-Myers Squibb's Q2 profit slips on highe... [Published FirstWord Pharma - Jul 25 2014]
Bristol-Myers Squibb Company's (BMY) CEO Lamber... [Published Yahoo! Finance - Jul 24 2014]
BMS and Ono Pharmaceutical announce strategic i... [Published European Pharmaceutical Manufacturer - Jul 24 2014]
BMS, Ono Collaborate on Immuno-Oncology [Published Drug Discovery and Development - Jul 24 2014]
Bristol Myers-Squibb 2nd-qtr sales dip 4% but s... [Published Pharma Letter - Jul 24 2014]
Bristol-Myers Squibb's Q2 profit falls on highe... [Published FirstWord Pharma - Jul 24 2014]
Bristol-Myers Squibb and Ono Pharmaceutical agr... [Published Manufacturing Chemist - Jul 24 2014]
ONO PHARMACEUTICAL : and Bristol-Myers Squibb A... [Published 4 Traders - Jul 24 2014]
Bristol-Myers Squibb and Ono Pharmaceutical Co.... [Published Investor's Business Daily - Jul 24 2014]
Bristol-Myers Squibb and Ono Pharmaceutical Co.... [Published Wall Street Select - Jul 24 2014]
Japan Approves First All-Oral, Interferon- and ... [Published National AIDS Treatment Advocacy Project - Jul 16 2014]
Bristol-Myers receives approval from MHLW for h... [Published Individual.com - Jul 14 2014]
CEO’s Letter: The stubborn facts about the 100 ... [Published CRO - Jul 09 2014]
Japan approves Daklinza, Sunvepra to treat HCV [Published Orthopedics Today - Jul 08 2014]
Bristol-Myers Squibb Treatment for Hepatitis C ... [Published Zolmax News - Jul 07 2014]
Bristol-Myers' hep C combo wins Japanese OK, le... [Published FierceBiotech - Jul 07 2014]
Bristol-Myers Squibb's Daklinza, Sunvepra all-o... [Published FirstWord Pharma - Jul 07 2014]
Eliquis scores DVT/PE recommendation in Europe [Published FiercePharma - Jun 27 2014]
Bristol-Myers Squibb's (BMY) CEO John Elicker o... [Published The Street Latest - Apr 30 2014]
Bristol-Myers Squibb net earnings up by 54% in Q1 [Published PharmaBiz - Apr 30 2014]
Product Positioning 2.0 [Published Pharmaceutical Executive - Feb 05 2014]
Bristol-Myers Squibb net falls by 21.5% in Q4 [Published PharmaBiz - Jan 27 2014]
J.P. Morgan: Pharma’s Agenda for 2014 [Published Pharmaceutical Executive - Jan 20 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.